Shots:

• Mersana to receive $40M up front & is eligible to receive reimbursement of certain costs, ~$1B in milestone payments along with royalties on global net sales of ADCs against the selected targets
• The companies collaborated on target products during preclinical development. Janssen will be responsible for clinical development and commercialization & provide Abs for three targets
• The agreement will utilize Synaffix’s GlycoConnect technology as site-specific ADC bioconjugation technology along with Mersana’s ADC expertise and the Dolasynthen platform to discover novel ADC product candidates

Ref: Mersana | Image: Menafn